Matthias Luz

Chief Medical Officer MedGenesis Therapeutics Inc.


Dr. Luz is a board-certified anesthesiologist and intensive care physician with an extensive background in epidemiology, clinical trial methodology and global regulatory affairs.  In addition to six years of clinical experience, Dr. Luz has 20 years of global product development and management experience in the biopharmaceutical and clinical research industry.  In his capacity as Chief Medical Officer, Dr. Luz oversees all development activities at MedGenesis.  Before joining MedGenesis in 2006, Dr. Luz was the Vice President and Head, Global Product Development Services for PRA International.  In this capacity, Dr. Luz led a worldwide team of senior physicians/scientists and accomplished drug development experts involved in the design and implementation of high quality development programs from pre-IND to Phase III and submission.  During a previous tenure at Behringwerke/Hoechst Marion Roussel/Aventis, Dr. Luz led the team that brought Refludan®, the first therapeutic for heparin-induced thrombocytopenia, to market worldwide.  Dr. Luz also held other senior positions at Knoll/Abbott and Cardion.